SAN DIEGO, May 17, 2017 /PRNewswire/ -- ResMed today
issued the following statement from David
Pendarvis, the company's global general counsel and chief
administrative officer:
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/74629527-resmed-patent-infringement-case-against-fisher-paykel/
"ResMed filed a motion to dismiss the current International
Trade Commission (ITC) complaint so that we can refile and
incorporate additional evidence generated since the original
complaint was filed. We believe this will make our strong case even
stronger, and we remain confident in our position in the ITC.
ResMed's innovations have transformed the treatment of
sleep-disordered breathing. We're committed to protecting our
innovation, which is why we've engaged in global legal proceedings
with Fisher & Paykel."
About ResMed
ResMed (NYSE: RMD) changes lives with
award-winning medical devices and cloud-based software applications
that better diagnose, treat and manage sleep apnea, chronic
obstructive pulmonary disease (COPD) and other chronic diseases.
ResMed is a global leader in connected care, with more than 3
million patients remotely monitored every day. Our 5,000-strong
team is committed to creating the world's best tech-driven medical
device company – improving quality of life, reducing the impact of
chronic disease, and saving healthcare costs in more than 100
countries. ResMed.com | Facebook | Twitter | LinkedIn
|
For
media:
|
For
investors:
|
|
Alison
Graves
|
Agnes Lee
|
|
858-836-6789
|
858-836-5971
|
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a